Zydus continues novel research efforts with I-O combo

9 March 2020
zydus-big-1

Zydus Cadila, a part of Cadila Healthcare (BOM: 532321), has agreed a licensing deal with California's XOMA Corporation (Nasdaq: XOMA) for a new combination therapy in immuno-oncology.

The Ahmedabad-based firm will offer its interleukin (IL)-2 candidate, while XOMA brings a novel anti-IL-2 monoclonal antibody to the table.

Zydus will develop the combination therapy from human proof-of-concept studies through to the formal clinical trial process.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology